Abstract
Of 36 patients with ovarian carcinoma treated with treosulfan (dihydroxybusulphan) 30·5 per cent had a complete response for a mean of 19·0 months and 33·3 per cent had a partial response. Treosulfan may have a role in the management of ascites associated with ovarian neoplasm.

This publication has 8 references indexed in Scilit: